{"id":"high-dose-potent-statin","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes"},{"rate":"1-2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit the enzyme HMG-CoA reductase, which catalyzes an early rate-limiting step in cholesterol biosynthesis. By reducing hepatic cholesterol production, statins trigger upregulation of LDL receptors on liver cells, increasing clearance of LDL cholesterol from circulation. High-dose formulations achieve greater LDL reduction and are used in patients requiring intensive lipid lowering.","oneSentence":"High-dose potent statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:24:22.895Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT01544309","phase":"NA","title":"LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts","status":"COMPLETED","sponsor":"Listen Trial Group","startDate":"2012-03","conditions":"Hypercholesterolemia With Concomitant Type 2 Diabetes","enrollment":1049}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["atorvastatin or rosuvastatin"],"phase":"marketed","status":"active","brandName":"High dose potent statin","genericName":"High dose potent statin","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose potent statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}